万古霉素联合哌拉西林-他唑巴坦与成人急性肾损伤:系统评价与Meta分析
该系统评价与Meta分析检索PubMed、Embase、Web of Science和Cochrane(至2017年4月),纳入15项已发表研究和17篇会议摘要,至少24799例患者。万古霉素联合哌拉西林-他唑巴坦的急性肾损伤发生率为22.2%,对照为12.9%,总体需伤害人数为11。与万古霉素单药(OR 3.40)、万古霉素联合头孢吡肟或碳青霉烯类(OR 2.68)、哌拉西林-他唑巴坦单药(OR 2.70)相比,联合方案的急性肾损伤风险均升高。在968例危重症患者的小样本亚组分析中,联合方案较万古霉素单药风险升高(OR 9.62),但与万古霉素联合头孢吡肟或碳青霉烯类(OR 1.43)或哌拉西林-他唑巴坦单药(OR 1.35)无显著差异。
要点
- 万古霉素联合哌拉西林-他唑巴坦的急性肾损伤发生率为22.2%,对照为12.9%,总体需伤害人数为11。
- 与万古霉素单药相比,联合方案急性肾损伤的OR为3.40(95%CI 2.57-4.50)。
- 与万古霉素联合头孢吡肟或碳青霉烯类相比,联合方案急性肾损伤的OR为2.68(95%CI 1.83-3.91)。
- 与哌拉西林-他唑巴坦单药相比,联合方案急性肾损伤的OR为2.70(95%CI 1.97-3.69)。
- 在968例危重症患者亚组中,联合方案较万古霉素单药OR 9.62(95%CI 4.48-20.68),但与万古霉素联合头孢吡肟或碳青霉烯类(OR 1.43,95%CI 0.83-2.47)或哌拉西林-他唑巴坦单药(OR 1.35,95%CI 0.86-2.11)无显著差异。
适用人群与场景
- 成人患者,包括危重症成人(亚组分析968例)。
- 排除非英文文献、儿科研究和病例报告。
研究设计与关键结果
- 系统评价与Meta分析,检索PubMed、Embase、Web of Science和Cochrane(至2017年4月),纳入15项已发表研究和17篇会议摘要,至少24799例患者。
- 万古霉素联合哌拉西林-他唑巴坦的急性肾损伤总体发生率为22.2%,对照为12.9%,总体需伤害人数为11。
- 与万古霉素单药相比,联合方案急性肾损伤的OR为3.40(95%CI 2.57-4.50)。
- 与万古霉素联合头孢吡肟或碳青霉烯类相比,联合方案急性肾损伤的OR为2.68(95%CI 1.83-3.91)。
- 与哌拉西林-他唑巴坦单药相比,联合方案急性肾损伤的OR为2.70(95%CI 1.97-3.69)。
- 急性肾损伤发生时间:联合方案较万古霉素联合头孢吡肟或碳青霉烯类更快,但无统计学显著差异(平均差-1.30天,95%CI -3.00至0.41天)。
- 危重症患者亚组(968例):联合方案较万古霉素单药OR 9.62(95%CI 4.48-20.68);与万古霉素联合头孢吡肟或碳青霉烯类OR 1.43(95%CI 0.83-2.47)、与哌拉西林-他唑巴坦单药OR 1.35(95%CI 0.86-2.11)无显著差异。
证据类型、等级与局限
- 证据类型:系统评价与Meta分析。
- 局限性:危重症患者数据有限;需要进一步在危重症人群中进行研究。
对床旁实践的改变
- 作者认为,万古霉素联合哌拉西林-他唑巴坦较万古霉素单药、万古霉素联合头孢吡肟或碳青霉烯类、哌拉西林-他唑巴坦单药增加急性肾损伤的 odds。
- 作者认为,危重症患者数据有限,提示联合方案较万古霉素单药急性肾损伤 odds 增加,而较其他对照方案风险减轻。
- 作者建议,需要进一步在危重症人群中进行研究。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: The objective of this systematic review and meta-analysis was to assess acute kidney injury with combination therapy of vancomycin plus piperacillin-tazobactam, in general, adult patients and in critically ill adults. Rates of acute kidney injury, time to acute kidney injury, and odds of acute kidney injury were compared with vancomycin monotherapy, vancomycin plus cefepime or carbapenem, or piperacillin-tazobactam monotherapy.
DATA SOURCES: Studies were identified by searching Pubmed, Embase, Web of Science, and Cochrane from inception to April 2017. Abstracts from selected conference proceedings were manually searched.
STUDY SELECTION: Articles not in English, pediatric studies, and case reports were excluded.
DATA EXTRACTION: Two authors independently extracted data on study methods, rates of acute kidney injury, and time to acute kidney injury. Effect estimates and 95% CIs were calculated using the random effects model in RevMan 5.3.
DATA SYNTHESIS: Literature search identified 15 published studies and 17 conference abstracts with at least 24,799 patients. The overall occurrence rate of acute kidney injury was 16.7%, with 22.2% for vancomycin plus piperacillin-tazobactam and 12.9% for comparators. This yielded an overall number needed to harm of 11. Time to acute kidney injury was faster for vancomycin plus piperacillin-tazobactam than vancomycin plus cefepime or carbapenem, but not significantly (mean difference, -1.30; 95% CI, -3.00 to 0.41 d). The odds of acute kidney injury with vancomycin plus piperacillin-tazobactam were increased versus vancomycin monotherapy (odds ratio, 3.40; 95% CI, 2.57-4.50), versus vancomycin plus cefepime or carbapenem (odds ratio, 2.68; 95% CI, 1.83-3.91), and versus piperacillin-tazobactam monotherapy (odds ratio, 2.70; 95% CI, 1.97-3.69). In a small subanalysis of 968 critically ill patients, the odds of acute kidney injury were increased versus vancomycin monotherapy (odds ratio, 9.62; 95% CI, 4.48-20.68), but not significantly different for vancomycin plus cefepime or carbapenem (odds ratio, 1.43; 95% CI, 0.83-2.47) or piperacillin-tazobactam monotherapy (odds ratio, 1.35; 95% CI, 0.86-2.11).
CONCLUSIONS: The combination of vancomycin plus piperacillin-tazobactam increased the odds of acute kidney injury over vancomycin monotherapy, vancomycin plus cefepime or carbapenem, and piperacillin-tazobactam monotherapy. Limited data in critically ill patients suggest the odds of acute kidney injury are increased versus vancomycin monotherapy, and mitigated versus the other comparators. Further research in the critically ill population is needed.
参考来源
- Luther MK, Timbrook TT, Caffrey AR, et al. Vancomycin Plus Piperacillin-Tazobactam and Acute Kidney Injury in Adults: A Systematic Review and Meta-Analysis. Crit Care Med. 2018. PMID: 29088001. doi:10.1097/CCM.0000000000002769
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。